Safety and Effectiveness of the Ultrasonic Propulsion of Kidney Stones

NCT ID: NCT02028559

Last Updated: 2024-02-02

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

NA

Total Enrollment

84 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-01-31

Study Completion Date

2024-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study tests moving kidney stones using focused ultrasound (referred to as ultrasonic propulsion). The study includes multiple population groups to investigate the ability of our technology to: a) move stone fragments to a location within the kidney to improve their chances of passage, and thus reduce the occurrence of additional symptomatic events and retreatment or b) move a symptomatic stone to relieve symptoms and pain.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is an investigator initiated, NIH-funded study conducted by the University of Washington (UW). Our research group has developed a new, non-invasive technology using low intensity focused ultrasound to reposition kidney stones by imparting sufficient acoustic energy to physically move a stone. The focused ultrasound pulses are similar to pulses that may be used in elastography or acoustic radiation force imaging. Like conventional ultrasound, the probe is placed in contact with the patient's skin to image the stone following standard ultrasound imaging procedure. The same probe is then used to focus the ultrasound and apply a burst (a sequence of pulses) of acoustic force to push the stone. Brightness mode (B-mode) imaging is interleaved with the "pushing" pulses (Push-mode) to monitor stone movement. The user controls the burst amplitude. To limit heating at the probe surface, there is a slight delay before the operator can execute the next push.

In addition to undergoing the investigational procedure, the research activities include the following:

* subjects undergo a pain questionnaire before and after the procedure;
* the subject's skin in the area of probe placement is observed before and after the procedure;
* subjects are contacted once-a-week for 3 weeks to evaluate for potential adverse events, pain medication use, and, if applicable, stone passage;
* subjects are requested to undergo at least one follow-up imaging 4 - 12 weeks post-procedure;
* a review of each subject's medical records is conducted 90-days post-procedure to evaluate for additional effectiveness and safety events.
* Specifically for the residual fragment population (randomized control trial), subjects are contacted every 6 months for 3 years and their charted is reviewed for 5 years for stone growth, symptomatic, unscheduled medical visits, and surgery related to stones.

Subjects that qualify for the trial are recruited into different study arms (referred to as Population groups) based on their type of stone condition (de novo stone versus post-lithotripsy fragment), size of stone (≤ 5 mm or \> 5 mm), and management plan (clinical observation or surgical intervention). The objectives vary based upon the Population group. Subjects may qualify for more than one population group over time and may undergo the investigational procedure up to 4 times total (inclusive of both the left and right-side urinary tracts). Population groups 1-3 has been closed. Therefore, the details provided for this registration is for Population group 4.

1. First-in-Human Population (Closed): This was the initial group of subjects included under this clinical trial. This was a 15-subject feasibility that included a broad range of populations. This feasibility population formulated the basis for expanding the trial into a larger study addressing each population separately. This is encompassed in subject populations 2-5 below.
2. Acute Subject Population (Closed): All subjects undergo the investigational procedure. Subjects undergo the investigational procedure awake and in the clinic or emergency department (ED) setting. To qualify the subject must have clinical imaging confirmation of an obstructing stone with their pain managed and complete a urinalysis to assess infection risk. Ultrasonic propulsion is used with the intent to relieve the obstruction and associated pain. A subset of subjects were exposed to higher amplitude dislodging pulses, in addition to the ultrasonic propulsion pulses.
3. De Novo Subject Population (Closed): Subjects undergo the investigational procedure awake and in the clinic. To qualify the subject must have a de novo stone ≤ 5 mm or, if larger, be scheduled for surgical intervention on the same day. Ultrasonic propulsion is used with the intent to help facilitate stone passage (≤ 5 mm) or demonstrate the ability to move larger stones. In the case of subjects scheduled for URS, the investigative procedure can be conducted concurrently with the standard-of-care procedure (see bullet point #2 above).
4. URS Subject Population (Closed): Subjects undergo the investigational procedure while anesthetized and concurrently undergoing a ureteroscopy guided laser lithotripsy procedure (referred to herein as URS). To qualify the subject must have at least one stone ≤ 20 mm in the largest dimension and be scheduled for surgery. Ultrasonic propulsion may be used to move a de novo stone or stone fragments of varying sizes generated over the course of the URS procedure. Note that since these subjects are anesthetized, a pain questionnaire is not included as part of their protocol.
5. Residual Fragment Population: Subjects undergo the investigational procedure awake and in the clinic setting. To qualify the subject must have at least one residual fragment (≤ 5 mm in largest dimension) identified either on imaging or based on the investigator's interpretation of that imaging. This is a prospective, open-label, multicenter, randomized control trial (RCT) with a treatment arm and control arm. The only difference in protocol between the two arms is that only the treatment group undergoes the investigational procedure and the associated post-procedure pain questionnaire and the post-procedure skin surface inspection. Ultrasonic propulsion is used with the intent to demonstrate the ability of the ultrasonic propulsion device to reposition stones within the human kidney and the subsequent clinical benefit of facilitating stone passage and reducing stone burden to reduce relapse. This is the only population group recruited across more than one site - the UW and the VA Puget Sound Heathcare System.

The final data set collected from the study will be analyzed under two separate statistical analysis plan (SAPs) referred to as NIH SAP and Pivotal SAP.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Kidney Stones Nephrolithiasis Urolithiasis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

SINGLE

Outcome Assessors
Outcome Assessors a) evaluating imaging for stone growth, b) evaluating relatedness of safety events to the device/procedure or underlying stone condition, and c) evaluating relapse events are blind to the exposure condition.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment with Ultrasonic Propulsion

Subjects receive treatment with the Propulse 1 device. Intervention consists of the non-invasive application of ultrasound to move stones within the kidney and ureter.

Group Type EXPERIMENTAL

Propulse 1

Intervention Type DEVICE

Move kidney stones with Propulse 1 device.

Control

Subject follow same protocol as treatment group but do not receive the ultrasonic propulsion intervention.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Propulse 1

Move kidney stones with Propulse 1 device.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Individuals suspected of having at least one stone remaining from the lithotripsy procedure
* Individuals at least 4-weeks post-lithotripsy procedure
* Individuals with residual stone fragments ≤ 5 mm in largest dimension (individually)
* Individuals being managed with watchful waiting or medical therapy for stones

Exclusion Criteria

* Individuals under 18 years of age
* Individuals with non-echogenic stones
* Individuals unable or unwilling to comply with the follow-up requirements
* Individuals with a coagulation abnormality or taking blood thinners or other anticoagulant at clinically significant levels
* Individuals with mobility issues who are unable to comfortably lie for up to 30 minutes or roll from their back to their side
* Individuals belonging to a vulnerable group (pregnant, mentally disabled, physically disabled, prisoner, etc.)
* Individuals who have already received four previous ultrasonic propulsion procedures.
* Individuals who have received an ultrasonic propulsion treatment within the last 4 weeks.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

VA Puget Sound Health Care System

FED

Sponsor Role collaborator

University of Washington

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Jonathan Harper, MD

Assistant Professor, Urology

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jonathan Harper, MD

Role: PRINCIPAL_INVESTIGATOR

University of Washington

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

VA Puget Sound Health Care System

Seattle, Washington, United States

Site Status

University of Washington Department of Urology

Seattle, Washington, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Hall MK, Thiel J, Dunmire B, Samson PC, Kessler R, Sunaryo P, Sweet RM, Metzler IS, Chang HC, Gunn M, Dighe M, Anderson L, Popchoi C, Managuli R, Cunitz BW, Burke BH, Ding L, Gutierrez B, Liu Z, Sorensen MD, Wessells H, Bailey MR, Harper JD. First Series Using Ultrasonic Propulsion and Burst Wave Lithotripsy to Treat Ureteral Stones. J Urol. 2022 Nov;208(5):1075-1082. doi: 10.1097/JU.0000000000002864. Epub 2022 Nov 1.

Reference Type RESULT
PMID: 36205340 (View on PubMed)

Dai JC, Sorensen MD, Chang HC, Samson PC, Dunmire B, Cunitz BW, Thiel J, Liu Z, Bailey MR, Harper JD. Quantitative Assessment of Effectiveness of Ultrasonic Propulsion of Kidney Stones. J Endourol. 2019 Oct;33(10):850-857. doi: 10.1089/end.2019.0340. Epub 2019 Sep 25.

Reference Type RESULT
PMID: 31333058 (View on PubMed)

Harper JD, Cunitz BW, Dunmire B, Lee FC, Sorensen MD, Hsi RS, Thiel J, Wessells H, Lingeman JE, Bailey MR. First in Human Clinical Trial of Ultrasonic Propulsion of Kidney Stones. J Urol. 2016 Apr;195(4 Pt 1):956-64. doi: 10.1016/j.juro.2015.10.131. Epub 2015 Oct 30.

Reference Type RESULT
PMID: 26521719 (View on PubMed)

Sorensen MD, Dunmire B, Thiel J, Cunitz BW, Burke BH, Levchak BJ, Popchoi C, Holmes AE, Kucewicz JC, Hall MK, Dighe M, Dai JC, Cormack FC, Liu Z, Bailey MR, Porter MP, Harper JD. Randomized Controlled Trial of Ultrasonic Propulsion-Facilitated Clearance of Residual Kidney Stone Fragments vs Observation. J Urol. 2024 Dec;212(6):811-820. doi: 10.1097/JU.0000000000004186. Epub 2024 Aug 15.

Reference Type DERIVED
PMID: 39146526 (View on PubMed)

Harper JD, Metzler I, Hall MK, Chen TT, Maxwell AD, Cunitz BW, Dunmire B, Thiel J, Williams JC, Bailey MR, Sorensen MD. First In-Human Burst Wave Lithotripsy for Kidney Stone Comminution: Initial Two Case Studies. J Endourol. 2021 Apr;35(4):506-511. doi: 10.1089/end.2020.0725. Epub 2020 Nov 5.

Reference Type DERIVED
PMID: 32940089 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

STUDY00002746

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Lithotripsy for the Treatment of Gallstones
NCT00042549 TERMINATED PHASE4